R&D From in silico to in vivo: Why development strategy now dete... As discovery becomes faster and more accessible, the differentiator shifts downstream.
Sales & Marketing A fast start to 2026 signals continued investor confidence i... Key factors in Switzerland’s success that could make other European life sciences hubs more attractive to investors.
R&D The impact of generative AI on protein design for drug disco... Artificial Intelligence (AI) is at the heart of the latest global transformation, not least within the biopharmaceutical industry.
Digital Biopharma’s AI rally: Readiness not hype in 2025 The drumbeat of AI advancements over the last year has left us all breathless, wondering which benchmark will be broken next and which new problems we can solve in biology.
Digital Sponsored Scaling AI in life sciences: From automation to strategic tr... When talking about AI in pharma and life sciences marketing, we often focus on the automation of content creation, management, and delivery.
Digital Turning pilots into production: How to create, scale, and su... Pharmaceutical companies are eagerly pursuing GenAI products and use cases to generate value within their organisations.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
